In patients with stable coronary artery disease or low-risk ACS treated with zotarolimus-eluting stents, 3 months of dual antiplatelet therapy was noninferior to 12 months for NACCE, without significantly increasing the risk of stent thrombosis.
http://jama.jamanetwork.com/article.aspx?articleid=1765224
Filed under: Cardiology, EBM | Tagged: antiplatelet, cardiology, stent |
The Voice of Reason 
Leave a Reply